Airfinity launches new HPV solution for prophylactic vaccines and treatments

Posted on Dec 12, 2022

Introducing Airfinity's new solution, a comprehensive tool designed to give a holistic overview of the prophylactic landscape for human papillomavirus (HPV) infections.

The prophylactic HPV space is in the midst of a shake-up, which could see significant market shifts in the coming years.

Countries are expanding their eligibility criteria for HPV vaccines, changing their dose recommendations and emerging candidates look to threaten the market share of incumbent market leaders by launching at markedly lower prices.

Today, Airfinity is launching its first HPV Intelligence Report, with a corresponding platform expected in early 2023. The report provides an in-depth overview and analysis of the current 'state-of-play' in the market, which includes candidate benchmarking, clinical timelines, analysis on supply, price, immunisation schedules and vaccine uptake.

Airfinity's new HPV solution includes analysis across:

→ Pipeline overview to help you benchmark candidates in development and understand which are close to approval ​​​​​​→ Current news, deals & social media coverage to keep abreast of new announcements across development, partnerships, funding, acquisitions and the commentary surrounding these → Approvals landscape to understand where vaccines have been approved and for which populations, with a focus on G20 countries → Trials landscape to understand the clinical trial landscape over time, including trends in vaccine type, trial locations, administration routes etc. → Market share and size for current markets over time and the predicted impact of new approvals → Vaccination schedules to understand the eligible population, dose recommendations per country and how changes over time affect demand → Vaccination coverage to provide global and country-specific uptake by dose and demographic

If you're interested in viewing our launch report and discussing our upcoming platform, get in touch via

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022